Sridharan Gururangan

Sridharan Gururangan, FRCP

Greene Professor Of Neurosurgery

Department: MD-NEUROLOGICAL SURGERY
Business Phone: (352) 273-9000
Business Email: gururangan@ufl.edu

About Sridharan Gururangan

Sridharan Gururangan, FRCP (Edin.), received his medical degree in 1981 from the University of Madras Chennai, India, proceeded to train in pediatrics in the United Kingdom and eventually became a Member of the Royal College of Physicians, U.K, in 1988. He was subsequently elected to fellowship from the Royal College of Physicians in Edinburgh, U.K. in 2015. He became interested in treating children with cancer during his pediatric training in the U.K. and completed a leukemia research fellowship in Manchester, England. 

Dr. Gururangan moved to the United States in 1991 to pursue his interest in pediatric oncology at St. Jude Children’s Hospital in Memphis, Tenn. and the Memorial Sloan Kettering Cancer Center in New York where he completed his fellowship in pediatric hematology-oncology in 1999. Dr. Gururangan moved to North Carolina to practice at Duke University Medical Center as the director of pediatric neuro-oncology at the Preston Robert Tisch Brain Tumor Center. For 17 years, he treated more than 1,200 children with brain tumors there and led several innovative clinical trials through his interaction with other investigators nationwide. 

Dr. Gururangan joined the UF faculty as an endowed professor in the UF department of neurosurgery in 2016. He also holds a joint appointment in the UF department of pediatrics. He is board certified in pediatric hematology-oncology and neuro-oncology. 

He is passionate about treating children with brain cancer and has been a resource and source of support for countless patients and family members. 

Dr. Gururangan’s research interests are in developing new strategies for treatment of children with brain tumors with a special focus in the development of phase I and II trials of new drugs, including novel chemotherapy agents, small molecule inhibitors targeting receptor tyrosine kinases, anti-angiogenesis inhibitors, pharmacologic strategies that lead to reversal of drug resistance to alkylating agents, immunotherapy approaches to the treatment of recurrent medulloblastoma, and oncolytic viral therapy for neoplastic meningitis. His clinical research has led to more than 100 peer-reviewed publications in prestigious journals, five book chapters and more than 115 abstracts presented at various national and international scientific meetings. 

Dr. Gururangan has earned several awards for his work with pediatric cancer patients, including the Excellence in Pediatric Clinical Research Award from the Society for Neuro-Oncology and two Shining Star Awards from the Make-A-Wish Foundation. Dr. Gururangan is a member of the Pediatric Brain Tumor Consortium and the Children’s Oncology Group.

Board Certifications

  • Neuro-Oncology
    United Council of Neurologic Specialties
  • Pediatric Hematology-Oncology
    American Board of Pediatrics
  • Pediatrics
    American Board of Pediatrics

Clinical Profile

Specialties
  • Pediatrics
Subspecialties
  • Pediatric Hematology-Oncology
Areas of Interest
  • Brain tumor – children
  • Meningitis
  • Neurofibromatosis 2
  • Neurofibromatosis-1
  • Primary lymphoma of the brain

Research Profile

Dr. Gururangan’s research interests are in developing new strategies for treatment of children with brain tumors with a special focus in the development of phase I and II trials of new drugs, including novel chemotherapy agents, small molecule inhibitors targeting receptor tyrosine kinases, anti-angiogenesis inhibitors, pharmacologic strategies that lead to reversal of drug resistance to alkylating agents, immunotherapy approaches to the treatment of recurrent medulloblastoma, and oncolytic viral therapy for neoplastic meningitis. His clinical research has led to more than 100 peer-reviewed publications in prestigious journals, five book chapters and more than 115 abstracts presented at various national and international scientific meetings.

Areas of Interest
  • Cancer Genetics
  • Cell signaling pathways
  • Chemotherapy
  • Drug design
  • Immunotherapy
  • Neuro-Oncology
  • Targeted Cancer Therapy

Publications

2021
A Phase 2 Trial of Selumetinib in Children with Recurrent Optic Pathway and Hypothalamic Low-Grade Glioma without NF1: A Pediatric Brain Tumor Consortium Study.
Neuro-oncology. [DOI] 10.1093/neuonc/noab047. [PMID] 33631016.
2021
A phase I trial of the CDK 4/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: A Pediatric Brain Tumor Consortium study (PBTC-042).
Pediatric blood & cancer. 68(4) [DOI] 10.1002/pbc.28879. [PMID] 33405376.
2021
Integrated molecular and clinical analysis of low-grade gliomas in children with neurofibromatosis type 1 (NF1).
Acta neuropathologica. 141(4):605-617 [DOI] 10.1007/s00401-021-02276-5. [PMID] 33585982.
2021
Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 39(7):822-835 [DOI] 10.1200/JCO.20.01372. [PMID] 33405951.
2021
Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials.
Clinical cancer research : an official journal of the American Association for Cancer Research. [DOI] 10.1158/1078-0432.CCR-20-4731. [PMID] 33737307.
2020
Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study.
Acta neuropathologica. 139(2):223-241 [DOI] 10.1007/s00401-019-02111-y. [PMID] 31820118.
2020
Risk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trials.
Acta neuropathologica. 139(2):259-271 [DOI] 10.1007/s00401-019-02106-9. [PMID] 31802236.
2019
Acute neurotoxicity following vincristine due to Charcot-Marie-Tooth disease in a young child with medulloblastoma.
Neuro-oncology practice. 6(3):179-184 [DOI] 10.1093/nop/npz002. [PMID] 31385990.
2019
Integrated analysis of long-term growth and bone development in pediatric and adolescent patients receiving bevacizumab.
Pediatric blood & cancer. 66(2) [DOI] 10.1002/pbc.27487. [PMID] 30378286.
2019
Massive clonal expansion of medulloblastoma-specific T cells during adoptive cellular therapy.
Science advances. 5(11) [DOI] 10.1126/sciadv.aav9879. [PMID] 31807694.
2018
Best practices for the use of intracerebroventricular drug delivery devices.
Molecular genetics and metabolism. 124(3):184-188 [DOI] 10.1016/j.ymgme.2018.05.003. [PMID] 29793829.
2018
Heterogeneity within the PF-EPN-B ependymoma subgroup.
Acta neuropathologica. 136(2):227-237 [DOI] 10.1007/s00401-018-1888-x. [PMID] 30019219.
2017
Everolimus to treat aggressive retinal astrocytic hamartoma in tuberous sclerosis complex.
Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus. 21(4):328-331 [DOI] 10.1016/j.jaapos.2017.04.012. [PMID] 28733147.
2017
Intracerebroventricular Delivery as a Safe, Long-Term Route of Drug Administration.
Pediatric neurology. 67:23-35 [DOI] 10.1016/j.pediatrneurol.2016.10.022. [PMID] 28089765.
2017
Regulatory T cell subsets in patients with medulloblastoma at diagnosis and during standard irradiation and chemotherapy (PBTC N-11).
Cancer immunology, immunotherapy : CII. 66(12):1589-1595 [DOI] 10.1007/s00262-017-2051-6. [PMID] 28825123.
2017
The clinical and financial impact of a pediatric surgical neuro-oncology clinical trial.
Journal of neuro-oncology. 132(1):83-87 [DOI] 10.1007/s11060-016-2338-z. [PMID] 27864705.
2016
Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation.
British journal of clinical pharmacology. 81(1):148-60 [DOI] 10.1111/bcp.12778. [PMID] 26345283.
2016
Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis.
The Lancet. Oncology. 17(4):484-495 [DOI] 10.1016/S1470-2045(15)00581-1. [PMID] 26976201.
2016
Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34(21):2468-77 [DOI] 10.1200/JCO.2015.65.7825. [PMID] 27269943.
2015
Corrigendum: Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss.
Nature genetics. 47(4) [DOI] 10.1038/ng0415-423. [PMID] 25814313.
2015
Ex vivo generation of dendritic cells from cryopreserved, post-induction chemotherapy, mobilized leukapheresis from pediatric patients with medulloblastoma.
Journal of neuro-oncology. 125(1):65-74 [DOI] 10.1007/s11060-015-1890-2. [PMID] 26311248.
2015
Gorlin syndrome and desmoplastic medulloblastoma: Report of 3 cases with unfavorable clinical course and novel mutations.
Pediatric blood & cancer. 62(10):1855-8 [DOI] 10.1002/pbc.25560. [PMID] 25940061.
2015
Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study.
Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery. 31(8):1283-9 [DOI] 10.1007/s00381-015-2725-3. [PMID] 25930724.
2015
Prognostic marker analysis in pediatric intracranial ependymomas.
Journal of neuro-oncology. 122(2):255-61 [DOI] 10.1007/s11060-014-1711-z. [PMID] 25563815.
2015
Pulmonary Function After Treatment for Embryonal Brain Tumors on SJMB03 That Included Craniospinal Irradiation.
International journal of radiation oncology, biology, physics. 93(1):47-53 [DOI] 10.1016/j.ijrobp.2015.05.019. [PMID] 26279023.
2015
Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 33(24):2646-54 [DOI] 10.1200/JCO.2014.60.1591. [PMID] 26169613.
2014
Clinico-pathological description of three paediatric medulloblastoma cases with MLL2/3 gene mutations.
Neuropathology and applied neurobiology. 40(2):217-20 [DOI] 10.1111/nan.12060. [PMID] 23659599.
2014
CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity.
Acta neuropathologica. 128(2):291-303 [DOI] 10.1007/s00401-014-1291-1. [PMID] 24839957.
2014
Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma.
Pediatric blood & cancer. 61(4):601-5 [DOI] 10.1002/pbc.24830. [PMID] 24504791.
2014
Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma.
Neuro-oncology. 16(6):848-55 [DOI] 10.1093/neuonc/not241. [PMID] 24414535.
2014
Molecular variants and mutations in medulloblastoma.
Pharmacogenomics and personalized medicine. 7:43-51 [DOI] 10.2147/PGPM.S38698. [PMID] 24523595.
2013
A phase-1 pharmacokinetic optimal dosing study of intraventricular topotecan for children with neoplastic meningitis: a Pediatric Brain Tumor Consortium study.
Pediatric blood & cancer. 60(4):627-32 [DOI] 10.1002/pbc.24309. [PMID] 23002039.
2013
Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022).
Cancer. 119(23):4180-7 [DOI] 10.1002/cncr.28343. [PMID] 24104527.
2013
Bevacizumab-associated osteonecrosis of the wrist and knee in three pediatric patients with recurrent CNS tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(2):e24-7 [DOI] 10.1200/JCO.2012.43.6733. [PMID] 23169504.
2013
Exploratory evaluation of MR permeability with 18F-FDG PET mapping in pediatric brain tumors: a report from the Pediatric Brain Tumor Consortium.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 54(8):1237-43 [DOI] 10.2967/jnumed.112.115782. [PMID] 23801675.
2013
Phase I trial of capecitabine rapidly disintegrating tablets and concomitant radiation therapy in children with newly diagnosed brainstem gliomas and high-grade gliomas.
Neuro-oncology. 15(6):759-66 [DOI] 10.1093/neuonc/nos315. [PMID] 23592571.
2013
Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis.
The Lancet. Oncology. 14(12):1200-7 [DOI] 10.1016/S1470-2045(13)70449-2. [PMID] 24140199.
2013
Sluggish cognitive tempo in survivors of pediatric brain tumors.
Journal of neuro-oncology. 114(1):71-8 [DOI] 10.1007/s11060-013-1149-8. [PMID] 23661102.
2012
A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study.
Journal of neuro-oncology. 106(3):643-9 [DOI] 10.1007/s11060-011-0709-z. [PMID] 21968943.
2012
Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma–a Pediatric Brain Tumor Consortium study.
Neuro-oncology. 14(11):1404-12 [DOI] 10.1093/neuonc/nos213. [PMID] 23019233.
2012
Novel mutations target distinct subgroups of medulloblastoma.
Nature. 488(7409):43-8 [DOI] 10.1038/nature11213. [PMID] 22722829.
2012
Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.
Journal of neuro-oncology. 107(1):155-64 [DOI] 10.1007/s11060-011-0722-2. [PMID] 21986722.
2012
Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.
Cancer. 118(19):4759-67 [DOI] 10.1002/cncr.26541. [PMID] 22371319.
2012
Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.
Journal of neuro-oncology. 106(2):409-15 [DOI] 10.1007/s11060-011-0687-1. [PMID] 21938530.
2012
Pilot study of systemic and intrathecal mafosfamide followed by conformal radiation for infants with intracranial central nervous system tumors: a pediatric brain tumor consortium study (PBTC-001).
Journal of neuro-oncology. 109(3):565-71 [DOI] 10.1007/s11060-012-0929-x. [PMID] 22790443.
2011
A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.
Journal of the National Comprehensive Cancer Network : JNCCN. 9(4):414-27 [PMID] 21464146.
View on: PubMed
2011
Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
Journal of neuro-oncology. 101(1):57-66 [DOI] 10.1007/s11060-010-0217-6. [PMID] 20443129.
2011
Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
Cancer. 117(23):5351-8 [DOI] 10.1002/cncr.26188. [PMID] 21590689.
2011
Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma.
Journal of neuro-oncology. 105(3):621-7 [DOI] 10.1007/s11060-011-0631-4. [PMID] 21744079.
2011
Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(26):3529-34 [DOI] 10.1200/JCO.2011.35.7806. [PMID] 21825264.
2011
Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
Journal of neuro-oncology. 103(2):371-9 [DOI] 10.1007/s11060-010-0403-6. [PMID] 20853132.
2011
Proteomic profiling of cerebrospinal fluid identifies prostaglandin D2 synthase as a putative biomarker for pediatric medulloblastoma: A pediatric brain tumor consortium study.
Proteomics. 11(5):935-43 [DOI] 10.1002/pmic.201000198. [PMID] 21271676.
2011
Transformation of juvenile pilocytic astrocytoma to anaplastic pilocytic astrocytoma in patients with neurofibromatosis type I.
Journal of pediatric hematology/oncology. 33(5):e198-201 [DOI] 10.1097/MPH.0b013e318205e230. [PMID] 21572348.
2010
A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas.
European journal of cancer (Oxford, England : 1990). 46(18):3287-93 [DOI] 10.1016/j.ejca.2010.07.005. [PMID] 20708924.
2010
Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(18):3069-75 [DOI] 10.1200/JCO.2009.26.8789. [PMID] 20479404.
2010
Non-cerebellar primitive neuroectodermal tumors (PNET): summary of the Milan consensus and state of the art workshop on marrow ablative chemotherapy with hematopoietic cell rescue for malignant brain tumors of childhood and adolescents.
Pediatric blood & cancer. 54(4):638-40 [DOI] 10.1002/pbc.22373. [PMID] 20146218.
2010
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.
Journal of neuro-oncology. 96(2):219-30 [DOI] 10.1007/s11060-009-9950-0. [PMID] 19562254.
2010
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.
Neuro-oncology. 12(12):1300-10 [DOI] 10.1093/neuonc/noq099. [PMID] 20716591.
2010
Trilateral retinoblastoma: potentially curable with intensive chemotherapy.
Pediatric blood & cancer. 54(3):384-7 [DOI] 10.1002/pbc.22336. [PMID] 19908299.
2009
Carboplatin-based primary chemotherapy for infants and young children with CNS tumors.
Cancer. 115(14):3243-53 [DOI] 10.1002/cncr.24362. [PMID] 19484793.
2009
Late effects of chemotherapy.
Cancer treatment and research. 150:43-65 [DOI] 10.1007/b109924_4. [PMID] 19834661.
2009
Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study.
British journal of cancer. 101(12):1986-94 [DOI] 10.1038/sj.bjc.6605412. [PMID] 19920819.
2009
Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.
Cancer. 115(13):2964-70 [DOI] 10.1002/cncr.24336. [PMID] 19402172.
2009
Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.
Cancer. 115(10):2188-98 [DOI] 10.1002/cncr.24213. [PMID] 19248046.
2009
Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.
Neuro-oncology. 11(5):556-61 [DOI] 10.1215/15228517-2009-007. [PMID] 19289491.
2009
Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme.
Clinical cancer research : an official journal of the American Association for Cancer Research. 15(3):1064-8 [DOI] 10.1158/1078-0432.CCR-08-2130. [PMID] 19188181.
2009
Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(8):1262-7 [DOI] 10.1200/JCO.2008.18.8417. [PMID] 19204199.
2008
Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(22):3749-55 [DOI] 10.1200/JCO.2007.14.3974. [PMID] 18669462.
2008
Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
Clinical cancer research : an official journal of the American Association for Cancer Research. 14(21):7068-73 [DOI] 10.1158/1078-0432.CCR-08-0260. [PMID] 18981004.
2008
Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma.
Neuro-oncology. 10(5):745-51 [DOI] 10.1215/15228517-2008-044. [PMID] 18755919.
2008
Hydrocephalus as a possible additional contributor to cognitive outcome in survivors of pediatric medulloblastoma.
Psycho-oncology. 17(11):1157-61 [DOI] 10.1002/pon.1349. [PMID] 18636431.
2008
Identification of distinct and overlapping cortical areas for bilingual naming and reading using cortical stimulation. Case report.
Journal of neurosurgery. Pediatrics. 1(3):247-54 [DOI] 10.3171/PED/2008/1/3/247. [PMID] 18352772.
2008
Initial testing of VNP40101M (Cloretazine) by the pediatric preclinical testing program.
Pediatric blood & cancer. 51(3):439-41 [DOI] 10.1002/pbc.21620. [PMID] 18493996.
2008
Multifocal anaplastic astrocytoma in a patient with hereditary colorectal cancer, transcobalamin II deficiency, agenesis of the corpus callosum, mental retardation, and inherited PMS2 mutation.
Neuro-oncology. 10(1):93-7 [PMID] 17993636.
View on: PubMed
2008
Perioperative factor IX replacement for surgical resection of a suprasellar astrocytoma in a child with severe haemophilia B.
Haemophilia : the official journal of the World Federation of Hemophilia. 14(2):387-9 [DOI] 10.1111/j.1365-2516.2007.01615.x. [PMID] 18194312.
2008
Phase I trial of VNP40101M (Cloretazine) in children with recurrent brain tumors: a pediatric brain tumor consortium study.
Clinical cancer research : an official journal of the American Association for Cancer Research. 14(4):1124-30 [DOI] 10.1158/1078-0432.CCR-07-4242. [PMID] 18281546.
2008
Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.
Neuro-oncology. 10(3):330-40 [DOI] 10.1215/15228517-2008-003. [PMID] 18359865.
2008
Social functioning and facial expression recognition in survivors of pediatric brain tumors.
Journal of pediatric psychology. 33(10):1142-52 [DOI] 10.1093/jpepsy/jsn035. [PMID] 18390896.
2007
Advances in the diagnosis and treatment of malignant childhood brain tumors.
Clinical advances in hematology & oncology : H&O. 5(2):120-2 [PMID] 17344801.
View on: PubMed
2007
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 25(30):4722-9 [PMID] 17947719.
View on: PubMed
2007
Determination of Cloretazine (VNP40101M) and its active metabolite (VNP4090CE) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS).
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 853(1-2):97-104 [PMID] 17446145.
View on: PubMed
2007
High-density single nucleotide polymorphism array analysis in patients with germline deletions of 22q11.2 and malignant rhabdoid tumor.
Human genetics. 122(2):117-27 [PMID] 17541642.
View on: PubMed
2007
Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP).
Blood. 110(10):3526-31 [PMID] 17698634.
View on: PubMed
2007
Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 25(21):3137-43 [PMID] 17634493.
View on: PubMed
2007
Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report.
Clinical cancer research : an official journal of the American Association for Cancer Research. 13(22 Pt 1):6712-8 [PMID] 18006772.
View on: PubMed
2007
Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.
Journal of neuro-oncology. 83(1):53-60 [PMID] 17245623.
View on: PubMed
2007
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.
Clinical cancer research : an official journal of the American Association for Cancer Research. 13(4):1253-9 [PMID] 17317837.
View on: PubMed
2007
Temozolomide in children with progressive low-grade glioma.
Neuro-oncology. 9(2):161-8 [PMID] 17347491.
View on: PubMed
2006
Central nervous system extraosseous Ewing sarcoma: radiologic manifestations of this newly defined pathologic entity.
AJNR. American journal of neuroradiology. 27(3):580-3 [PMID] 16551995.
View on: PubMed
2006
Incidence and patterns of neuraxis metastases in children with diffuse pontine glioma.
Journal of neuro-oncology. 77(2):207-12 [PMID] 16568209.
View on: PubMed
2006
Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 47(6):912-8 [PMID] 16741299.
View on: PubMed
2006
Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.
Clinical cancer research : an official journal of the American Association for Cancer Research. 12(3 Pt 1):860-8 [PMID] 16467100.
View on: PubMed
2006
Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004).
Clinical cancer research : an official journal of the American Association for Cancer Research. 12(5):1540-6 [PMID] 16533779.
View on: PubMed
2006
Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 24(1):115-22 [PMID] 16382120.
View on: PubMed
2005
Chemotherapy and novel therapeutic approaches in malignant glioma.
Frontiers in bioscience : a journal and virtual library. 10:2645-68 [PMID] 15970525.
View on: PubMed
2005
Intracranial Ewing sarcoma.
Pediatric blood & cancer. 45(6):850-6 [PMID] 15929128.
View on: PubMed
2005
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 23(36):9359-68 [PMID] 16361636.
View on: PubMed
2004
[18F]fluorodeoxyglucose-positron emission tomography in patients with medulloblastoma.
Neurosurgery. 55(6):1280-8; discussion 1288 [PMID] 15574210.
View on: PubMed
2004
Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.
Neuro-oncology. 6(2):145-53 [PMID] 15134629.
View on: PubMed
2004
Recent advances in the treatment of pediatric brain tumors.
Oncology (Williston Park, N.Y.). 18(13):1649-61; discussion 1662, 1665 [PMID] 15648297.
View on: PubMed
2004
Short-term efficacy of methylphenidate: a randomized, double-blind, placebo-controlled trial among survivors of childhood cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 22(23):4795-803 [PMID] 15570081.
View on: PubMed
2004
Trilateral retinoblastoma: clinical and radiologic progression.
AJR. American journal of roentgenology. 183(2):505-11 [PMID] 15269048.
View on: PubMed
2003
High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 21(11):2187-91 [PMID] 12775745.
View on: PubMed
2002
Innovations in design and delivery of chemotherapy for brain tumors.
Neuroimaging clinics of North America. 12(4):583-97 [PMID] 12687913.
View on: PubMed
2002
Phase II study of carboplatin in children with progressive low-grade gliomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 20(13):2951-8 [PMID] 12089224.
View on: PubMed
2002
Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.
Neuro-oncology. 4(2):102-8 [DOI] 10.1093/neuonc/4.2.109. [PMID] 11916501.
2002
Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 20(9):2277-83 [PMID] 11980998.
View on: PubMed
2001
Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas.
Neuro-oncology. 3(4):246-50 [DOI] 10.1093/neuonc/3.4.246. [PMID] 11584894.
2000
Outcome of CNS disease at diagnosis in disseminated small noncleaved-cell lymphoma and B-cell leukemia: a Children’s Cancer Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 18(10):2017-25 [PMID] 10811665.
View on: PubMed
1998
BRa (HPA-5b) incompatibility may cause thrombocytopenia in neonates of mothers with immune thrombocytopenic purpura.
Journal of pediatric hematology/oncology. 20(3):202-6 [PMID] 9628430.
View on: PubMed
1998
Treatment of children with peripheral primitive neuroectodermal tumor or extraosseous Ewing’s tumor with Ewing’s-directed therapy.
Journal of pediatric hematology/oncology. 20(1):55-61 [PMID] 9482414.
View on: PubMed
1994
Benign giant cell tumour of bone in a child with pulmonary metastases at presentation.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 20(6):700-2 [PMID] 7995428.
View on: PubMed
1994
Bone metastases in Wilms’ tumor–report of three cases and review of literature.
Pediatric radiology. 24(2):85-7 [PMID] 8078728.
View on: PubMed
1994
Peritoneal metastases in two patients with pineoblastoma and ventriculo-peritoneal shunts.
Medical and pediatric oncology. 22(6):417-20 [PMID] 8152405.
View on: PubMed
1994
Successful treatment of acute lymphoblastic leukemia in a child with cystic fibrosis.
Medical and pediatric oncology. 22(6):414-6 [PMID] 8152404.
View on: PubMed
1993
Ploidy changes between diagnosis and relapse in childhood renal tumours.
Urological research. 21(5):345-7 [PMID] 8279091.
View on: PubMed
1993
Primary extracranial rhabdoid tumors. Clinicopathologic features and response to ifosfamide.
Cancer. 71(8):2653-9 [PMID] 8453588.
View on: PubMed
1992
DNA quantitation of Wilms’ tumour (nephroblastoma) using flow cytometry and image analysis.
Journal of clinical pathology. 45(6):498-501 [PMID] 1320635.
View on: PubMed
1992
Evaluation of the usefulness of open lung biopsies.
Pediatric hematology and oncology. 9(2):107-13 [PMID] 1524987.
View on: PubMed
1992
Inflammatory pseudotumor of the liver masquerading as a metastasis in a child treated for nephroblastoma.
Medical and pediatric oncology. 20(2):172-5 [PMID] 1310343.
View on: PubMed
1992
Primary hepatic tumours in children: a 26-year review.
Journal of surgical oncology. 50(1):30-6 [PMID] 1315408.
View on: PubMed
1990
Ribavirin response in measles pneumonia.
The Journal of infection. 20(3):219-21 [PMID] 2341731.
View on: PubMed

Grants

Jul 2020 ACTIVE
Pediatric Brain Tumor ConsortiumA multi-institutional consortium devoted to novel phase I and II clinical evaluations of experimental treatment approaches for pediatric CNS tumors
Role: Principal Investigator
Funding: ST JUDE CHILDRENS RESEARCH HOSPITAL via NATL INST OF HLTH NCI
Jul 2020 ACTIVE
RNA-nanoparticle vaccines for pediatric high-grade glioma
Role: Co-Investigator
Funding: CURESEARCH FOR CHILDRENS CANCER
Jun 2020 ACTIVE
Multi-center phase I study evaluating lipid-nanoparticle vaccines against pediatric high-grade glioma
Role: Co-Investigator
Funding: FL DEPT OF HLTH LIVE LIKE BELLA
Dec 2019 – Dec 2020
Phase 1 Trial of Marizomib Alone and in Combination with Panobinostat for Children with Diffuse Intrinsic Pontine Glioma
Role: Principal Investigator
Funding: PEDIATRIC BRAIN TUMOR FOUNDATION
Nov 2017 ACTIVE
Selective Expansion of Neoantigen-Specific T Cells Targeting Medulloblastoma
Role: Co-Investigator
Funding: THE V FOU FOR CANCER RESEARCH
Jul 2017 – Jul 2020
Newly-Diagnosed Brain Stem Gliomas Treated with Adoptive Cellular Therapy During Recovery from Focal Radiotherapy Alone or Radiotherapy and Dose-intensified Temozolomide
Role: Principal Investigator
Funding: THE LYLA NSOULI FOU CHILDRENS BRAIN CANC
Jun 2017 – Jun 2020
Newly-Diagnosed Brain Stem Gliomas Treated with Adoptive Cellular Therapy during Recovery from Focal Radiotherapy Alone or Radiotherapy and Dose-intensified Temozolomide
Role: Principal Investigator
Funding: ACCELERATE BRAIN CANCER CURE

Education

FRCP
2015 · Royal College of Physicians, Edinburgh, Scotland (Conferred Degree)
Clinical Fellow, Pediatric Hematology
1996-1999 · New York Hospital, Cornell Medical Center New York, NY
Clinical Fellow, Pediatric Hematology/Oncology
1996-1999 · Memorial Sloan Kettering Cancer Center New York, NY
Clinical Fellow, Hematology/Oncology
1993-1994 · St. Jude Children’s Research Hospital Memphis, TN
Senior Resident, Pediatrics
1992-1993 · LeBonheur Children’s Medical Center
Clinical Fellow, Hematology/Oncology
1991-1992 · St. Jude Children’s Research Hospital Memphis, TN
Research Fellow, Pediatric Oncology
1991 · Our Lady’s Hospital for Sick Children Dublin, Republic of Ireland
Senior Resident, Pediatric Oncology
1990 · Our Lady’s Hospital for Sick Children Dublin, Republic of Ireland
Senior Resident, Pediatric Oncology
1988-1989 · Royal Manchester Children’s Hospital Manchester, U.K.
MRCP
1988 · Royal College of Physicians; London, England
Resident, Pediatric Oncology
1988 · Children’s Hospital Sheffield, U.K.
Resident, Pediatrics
1987-1988 · Children’s Hospital Sheffield, U.K.
Resident, Pediatrics
1987 · Royal Victoria Infirmary Newcastle, U.K.
Resident, Neonatal Medicine
1986-1987 · St. Mary’s Hospital Manchester, U.K.
Resident, Pediatrics
1986 · Prince Charles Hospital South Wales, U.K.
Resident, Pediatrics
1985 · Government Stanley Hospital Madras, India
Resident, General Medicine
1984-1985 · Southern Railway Headquarters Hospital Madras, India
Resident, General Medicine
1983-1984 · Government Stanley Hospital Madras, India
Rotating Intern
1982-1983 · Government Stanley Hospital Madras, India
MBBS
1981 · Madras University; Chennai, India
B.Sc. Chemistry
1976 · Loyola College; Madras India

Contact Details

Phones:
Business:
(352) 273-9000
Emails:
Business:
gururangan@ufl.edu
Administrative Assistant:
Danielle Carpenter
View Profile